Treatments · Eyelid · Demodex blepharitis · Updated May 2026
Private Xdemvy lotilaner blepharitis drops, UK 2026
Xdemvy is the Tarsus Pharmaceuticals topical lotilaner ophthalmic suspension 0.25 percent that paralyses Demodex folliculorum mites in the eyelash follicles to clear chronic Demodex blepharitis in a single six-week course.
Unlike tea tree oil scrubs, hypochlorous lid sprays or warm-compress regimes that suppress symptoms but rarely eradicate the mite load, lotilaner is a first-in-class GABA-Cl channel-blocking ectoparasiticide with a single FDA-approved indication (Demodex blepharitis). UK 2026 self-pay is typically GBP 285-450 per six-week course on a named-patient pathway via consultant private prescription.
Fast answer: private Xdemvy in the UK in 2026
Typical cost per course
GBP 285-450 per six-week course on a named-patient private prescription pathway, including consultant assessment, named-patient importation fee and structured follow-up.
What it does
Paralyses and clears Demodex folliculorum mites in the eyelash follicles by selective blockade of mite GABA-Cl channels, eradicating the root cause of chronic Demodex blepharitis.
Course length
One drop in each eye twice daily for six weeks. No tapering. Symptoms typically improve from week two and collarettes clear by week six on the Saturn-1 and Saturn-2 trial data.
UK availability
Restricted in 2026. Xdemvy is FDA-approved but not yet routinely stocked by UK pharmacies. Access is via consultant private prescription on a named-patient importation pathway.
What is Xdemvy (lotilaner ophthalmic suspension 0.25 percent)?
Xdemvy is the brand name for lotilaner ophthalmic suspension 0.25 percent, a sterile preservative-free topical eye drop developed by Tarsus Pharmaceuticals and approved by the US Food and Drug Administration in July 2023 for the treatment of Demodex blepharitis. Lotilaner is a first-in-class veterinary-grade and now ophthalmic-grade isoxazoline ectoparasiticide that selectively blocks the gamma-aminobutyric acid (GABA) chloride channels of arthropods including Demodex folliculorum, the eyelash mite responsible for most cases of chronic anterior blepharitis. Because human GABA-Cl channels have a very different binding pocket, lotilaner is selectively toxic to the mite and is poorly absorbed systemically when applied topically to the ocular surface.
Clinically, Demodex blepharitis presents with itching at the lash base, irritation worse in the morning, recurrent stye-like swellings, lash misdirection and the pathognomonic cylindrical collarettes wrapped around the base of the eyelash. It is the underlying cause of a large proportion of chronic chalazion recurrence, dry eye symptoms with meibomian gland dysfunction, and contact lens intolerance. Until Xdemvy, UK patients were managed with repeat tea-tree-oil based lid scrubs (terpinen-4-ol), hypochlorous-acid lid sprays, warm-compress regimes and oral ivermectin off-label. Lotilaner is the first licensed mite-specific eradication therapy, and its arrival changes the practical pathway for chronic Demodex blepharitis worldwide. A private Xdemvy course typically runs alongside a structured lid hygiene plan and, where indicated, LipiFlow or intense pulsed light (IPL) dry eye treatment for any coexisting meibomian gland dysfunction.
UK 2026 private Xdemvy cost per six-week course
Private Xdemvy is priced per six-week course and where available includes the consultant blepharitis and ocular surface assessment, slit-lamp microscopy and Demodex collarette grading, the named-patient importation fee for the lotilaner bottle, a written lid-hygiene plan and the structured six-week and three-month follow-up. UK 2026 self-pay sits at a premium relative to over-the-counter lid scrubs because the lotilaner active itself is supplied on a named-patient route until UK marketing authorisation is granted.
| Pathway | Typical UK 2026 self-pay cost |
|---|---|
| Consultant assessment + Demodex grading + lid hygiene plan | GBP 195-275 |
| Single Xdemvy bottle (named-patient importation, full six-week course) | GBP 285-450 |
| Bilateral package: assessment + Xdemvy + 6-week and 3-month follow-up | GBP 495-695 |
| Add-on: LipiFlow or IPL for coexisting meibomian gland dysfunction | From GBP 450 per eye, see related price lists |
Compare with the LipiFlow MGD price list, the private dry eye IPL price list and the chalazion treatment price list if your blepharitis has caused recurrent lid lumps. Stage payment via finance is available where the indication is met.
What is included in your private Xdemvy course
Consultant blepharitis assessment
A consultant-led ocular surface and lid margin examination at what to expect at your consultation, including slit-lamp Demodex collarette grading on a standardised scale.
Ocular surface workup
Tear film osmolarity, MMP-9 inflammation marker, meibography and tear break-up time to confirm whether coexisting meibomian gland dysfunction needs concurrent treatment.
Named-patient Xdemvy supply
A single full-course (5 mL) bottle of preservative-free lotilaner ophthalmic suspension 0.25 percent supplied via the clinic's named-patient importation specials pharmacy.
Lid hygiene plan
Written instructions, dose card and a recommended adjunctive lid hygiene routine using hypochlorous-acid sprays and warm compresses for the six-week treatment window.
Structured follow-up
Six-week end-of-treatment slit-lamp review and three-month durability review to confirm collarette clearance and to screen for symptom recurrence.
Direct consultant access
Continuity with your prescribing consultant ophthalmologist for any in-course query, including a transparent pathway to aftercare or repeat course planning.
What does the evidence say about lotilaner for Demodex blepharitis?
Lotilaner ophthalmic suspension 0.25 percent was approved by the FDA in July 2023 on the back of the Saturn-1 and Saturn-2 phase-3 pivotal trials. Saturn-1 enrolled 421 adults with Demodex blepharitis and grade two or higher collarettes; Saturn-2 enrolled 412. Patients were randomised to one drop in each eye twice daily of lotilaner 0.25 percent or vehicle for 43 days, with primary endpoints assessed at day 43. Across both trials, lotilaner achieved complete collarette cure (grade zero, less than two collarettes per upper lid) in approximately 44-56 percent of treated eyes versus 7-12 percent of vehicle eyes, complete mite eradication (zero mites per epilated lash) in approximately 67-70 percent versus 17-18 percent, and complete erythema cure in approximately 19-31 percent versus 6-9 percent. Adverse events were mild and predominantly instillation site stinging and burning.
Post-marketing 12-month durability data published through 2024 and 2025 indicate that the majority of responders maintain collarette clearance at six months and a meaningful minority maintain it through twelve months without retreatment. A retreatment course is reasonable for symptom recurrence and the safety profile of repeat dosing is acceptable in the available cohorts. Lotilaner is not yet held by every UK private specials pharmacy in 2026, so a named-patient importation lead time of one to two weeks is typical.
Xdemvy vs other Demodex and blepharitis treatments
Choosing a Demodex blepharitis treatment is a trade-off between mite-killing potency, ocular surface tolerability, dosing convenience, evidence base and current UK availability. Xdemvy is the only licensed mite-specific topical: most alternatives are either non-specific lid hygiene or repurposed treatments.
| Treatment | Mechanism | Course | Best suited to |
|---|---|---|---|
| Xdemvy (lotilaner 0.25 percent) | Selective mite GABA-Cl channel blocker, ectoparasiticide | One drop each eye twice daily for six weeks | Chronic Demodex blepharitis with confirmed collarettes who want true mite eradication |
| Tea tree oil 50 percent in-clinic scrubs (terpinen-4-ol) | Membrane-disruptive acaricide, requires direct lash margin contact | Weekly in-clinic scrub plus daily home wipes for 6-8 weeks | Patients who cannot access lotilaner or prefer a non-prescription pathway |
| Hypochlorous acid lid sprays (Avenova / similar) | Broad-spectrum antimicrobial, low mite activity | Twice-daily spray on closed lids, ongoing maintenance | Mild anterior blepharitis without confirmed Demodex, or maintenance after Xdemvy |
| Oral ivermectin (off-label, with topical permethrin) | Systemic macrocyclic lactone with mite GluCl activity | Two-dose oral course one week apart, repeated | Resistant Demodex with associated rosacea where systemic therapy is justified |
| Warm compress + meibomian expression | Liquefies meibum, no acaricidal effect | Daily 8-10 minute warm compress, ongoing | Patients with concurrent meibomian gland dysfunction, alongside Xdemvy or scrubs |
| In-clinic LipiFlow or intense pulsed light (IPL) | Thermal pulsation or photobiomodulation of meibomian glands | Single LipiFlow session or a course of 3-4 IPL sessions | Coexisting meibomian gland dysfunction driving evaporative dry eye |
See the in-depth LipiFlow MGD treatment page and the private dry eye IPL treatment page before deciding whether to combine Xdemvy with concurrent meibomian gland therapy.
Are you a candidate for Xdemvy?
Good candidates
- Adults aged 18 and over with chronic anterior blepharitis and a slit-lamp grade two or greater Demodex collarette load on the upper lashes.
- Patients with recurrent lash-base itching, irritation worse in the morning, recurrent chalazion formation or stye-like swellings.
- Patients who have tried tea-tree-oil scrubs, hypochlorous lid sprays or warm-compress regimes without durable resolution of collarettes or symptoms.
- Contact lens wearers with intolerance attributable to Demodex blepharitis on the lid margin.
- Patients planning future lid, cataract or refractive surgery who need lid margin disease eradicated before intervention.
Better suited to other options
- Patients with bacterial staphylococcal blepharitis without confirmed Demodex - lid hygiene and topical antibiotic ointment is the first-line.
- Patients whose dominant problem is pure meibomian gland dysfunction - LipiFlow or IPL is more targeted.
- Children under 18 - Xdemvy is not licensed in paediatric Demodex blepharitis.
- Patients pregnant or breastfeeding - lotilaner is not formally evaluated in this population, so use is on a case-by-case risk discussion.
- Patients with active corneal infection or recent intraocular surgery where any new topical is best deferred until the surface is stable.
NHS vs private Xdemvy in the UK
The NHS does not yet commission lotilaner ophthalmic suspension for Demodex blepharitis: NHS pathways centre on lid hygiene advice, hypochlorous lid sprays and warm compresses, with referral to ophthalmology for refractory disease or recurrent chalazia. Xdemvy is accessed in 2026 only on a private pathway via consultant prescription and named-patient importation. Private Xdemvy offers same-week consultant continuity, formal slit-lamp Demodex collarette grading, a written six-week treatment plan and structured end-of-treatment and three-month follow-up. See the wider conditions hub for the full anterior segment pathway and the treatments overview.
Insurance and funding
Major UK private medical insurers cover the consultant ocular surface assessment under outpatient ophthalmology benefits, but the Xdemvy drug supply itself - because it is named-patient importation in 2026 - is usually self-pay. We will give you an itemised quote splitting the consultant assessment that may be eligible for an insurance claim and the lotilaner drug element you self-fund. See insured patients for how we work with major UK insurers and finance for stage payment options on the self-pay element.
Risks and side effects of Xdemvy
Lotilaner ophthalmic suspension 0.25 percent is a topical preparation and has a favourable ocular surface profile. The most frequently reported adverse event in Saturn-1 and Saturn-2 was mild instillation site stinging or burning at the moment of administration, reported by approximately 10 percent of patients and almost always self-limiting within seconds. Other reported events were transient blurred vision, mild conjunctival hyperaemia and dry eye sensation, each below 2 percent. Systemic absorption is low and no clinically significant systemic adverse events have been linked to topical lotilaner in the pivotal or post-marketing data. Demodex blepharitis can recur over time after a successful course, and a repeat six-week course is a reasonable management option for confirmed recurrence with collarettes.
The six-week Xdemvy course timeline
Week 0 (consultation)
Consultant slit-lamp examination, collarette grading, tear film workup and named-patient prescription. Lotilaner bottle ordered from the specials pharmacy.
Week 1-2
One drop each eye twice daily, morning and evening, twelve hours apart. Mild stinging at instillation is common and settles within seconds. Symptoms typically begin to ease from day 7-10.
Week 3-5
Continue dosing. Collarettes begin to thin and clear from the lash base. Itching, lash-line crusting and morning irritation continue to fade. No tapering is needed.
Week 6 (end of course)
Final dose on day 43. Slit-lamp review to grade collarette clearance and confirm response. Transition to a maintenance lid hygiene routine.
Month 3 review
Durability check at three months to confirm sustained collarette clearance and to screen for early symptom recurrence that may benefit from a repeat course.
How to choose a UK Xdemvy clinic
- Confirm the prescriber is a GMC-registered consultant ophthalmologist with documented experience in ocular surface disease and Demodex blepharitis management.
- Insist on a formal slit-lamp Demodex collarette grading before any drug is dispensed: lotilaner without confirmed Demodex is poor practice.
- Check that lotilaner is supplied through a regulated UK specials pharmacy on a named-patient pathway, with a clear chain of custody and within-date expiry.
- Confirm the clinic uses preservative-free lotilaner ophthalmic suspension 0.25 percent in the original branded packaging - never decanted or compounded.
- Ask whether tear film osmolarity, MMP-9 and meibography are performed at baseline to identify coexisting meibomian gland dysfunction.
- Insist on a structured six-week end-of-treatment review and a three-month durability review, included in the package price.
- Insist on a written, itemised quote covering the consultant assessment, drug supply, follow-up and any later repeat course or adjunctive treatment.
See our consultant ophthalmology team and the treatments hub for the wider anterior segment service, or review the chalazion pricing if recurrent lid lumps are a feature of your blepharitis.
Xdemvy frequently asked questions
How much does a private Xdemvy course cost in the UK in 2026?
Self-pay Xdemvy in the UK in 2026 is typically GBP 285-450 for a single full-course (5 mL) bottle on a named-patient importation pathway. A full clinical package including consultant assessment, Demodex grading, the lotilaner bottle, lid hygiene plan and the six-week and three-month reviews is typically GBP 495-695 in total. Pricing reflects the named-patient route and the absence of a UK marketing authorisation in 2026.
Is Xdemvy available on the NHS?
No. The NHS does not currently commission lotilaner ophthalmic suspension for Demodex blepharitis. NHS pathways centre on lid hygiene, hypochlorous lid sprays and warm compresses, with referral to ophthalmology for refractory disease. Xdemvy is accessed only on a private pathway via consultant prescription and named-patient importation in 2026.
How does Xdemvy work to clear Demodex blepharitis?
Lotilaner selectively blocks the gamma-aminobutyric acid chloride (GABA-Cl) channel of Demodex folliculorum, paralysing and killing the mite. Because human GABA-Cl channels have a very different binding pocket, lotilaner is selectively toxic to the mite and very poorly absorbed systemically when applied topically to the ocular surface.
How long does a Xdemvy course take to clear blepharitis?
The Xdemvy course is one drop in each eye twice daily for six weeks (43 days). On the Saturn-1 and Saturn-2 trial data, symptoms typically begin to ease from week two, collarettes thin and clear progressively from week three, and the primary endpoint of complete collarette cure is assessed at day 43.
Can I get Xdemvy without a prescription in the UK?
No. Xdemvy is a prescription-only medicine and, until UK marketing authorisation is granted, it is supplied in the UK only on a named-patient importation pathway via a regulated specials pharmacy following consultant prescription. It is not available over the counter.
What are the most common side effects of Xdemvy?
The most frequently reported adverse event in the pivotal Saturn-1 and Saturn-2 trials was mild instillation site stinging or burning, reported by approximately 10 percent of patients and almost always self-limiting within seconds. Other reported events including transient blurred vision, mild conjunctival redness and dry eye sensation were each below 2 percent.
Can I wear contact lenses during a Xdemvy course?
Lotilaner ophthalmic suspension 0.25 percent should not be administered while contact lenses are in the eye. Lenses should be removed before instillation and may be reinserted after 15 minutes. Many patients with Demodex blepharitis have lens intolerance that improves substantially once the underlying mite load is cleared.
Will Demodex blepharitis come back after Xdemvy?
Most patients who achieve complete collarette clearance at day 43 maintain that response for several months. A meaningful minority remain clear at twelve months without retreatment. Recurrence can occur over time, and a repeat six-week Xdemvy course is a reasonable management option for confirmed recurrence with collarettes.
Xdemvy vs tea tree oil scrubs - which works better?
Lotilaner is the only treatment with phase-3 pivotal trial evidence of complete mite eradication and complete collarette clearance in Demodex blepharitis. Tea tree oil scrubs at clinical concentrations (50 percent terpinen-4-ol) can suppress mite load but require weekly in-clinic application and have a higher ocular surface irritation profile. Xdemvy is the preferred first-line where it can be accessed.
Can children use Xdemvy?
Xdemvy is licensed for adults aged 18 and over with Demodex blepharitis. It is not licensed for paediatric use. Paediatric blepharitis is managed with conservative lid hygiene and specialist paediatric ophthalmology input.
Can I use Xdemvy if I am pregnant or breastfeeding?
Lotilaner has not been formally evaluated in pregnancy or lactation. Although topical systemic absorption is very low, prescription in pregnancy or breastfeeding is on a case-by-case basis after a documented risk-benefit discussion with your consultant ophthalmologist. Many patients defer treatment until after delivery or weaning.
Where can I book a private Xdemvy consultation in the UK?
Book a free online consultation or an in-person assessment with our consultant ophthalmology team through the eyesurgeryclinic.co.uk booking pages or call 0800 852 7782 to be triaged the same week and to confirm current Xdemvy availability and lead time.
Methodology and sources
Pricing is taken from a 2026 UK private blepharitis tariff audit across CQC-regulated providers offering lotilaner ophthalmic suspension on a named-patient pathway and is presented as a typical self-pay range for the consultant assessment and the lotilaner bottle. Clinical statements are drawn from the FDA Xdemvy prescribing information (Tarsus Pharmaceuticals, July 2023), the Saturn-1 and Saturn-2 pivotal trial publications (Yeu et al, Cornea; Gaddie et al, JAMA Ophthalmology), 12-month post-marketing safety and durability data published through 2024-2025, the American Academy of Ophthalmology Preferred Practice Pattern on blepharitis, and the Royal College of Ophthalmologists guidance on ocular surface disease. Page last reviewed 27 May 2026 against the live URL set on eyesurgeryclinic.co.uk.
Book a consultant blepharitis assessment
Find out whether private Xdemvy is the right treatment for your chronic Demodex blepharitis with a same-week consultant ophthalmology assessment, formal slit-lamp Demodex collarette grading and a written six-week treatment plan with transparent UK 2026 pricing.
Or call 0800 852 7782.
Back to Treatments